1. Changing The Future of Medicine Sales Call Week 5 Oct. 25, 2013

2. Today’s Agenda Changing The Future of Medicine Review our 3 Main Studies PILL RACER OSCAR Professional Services Agreement Clinical Research Services

3. Clinical Research Model Patient Enrollment into Studies Reimbursing Physicians = Proprietary & Patented Protected our Business Model from Competition

4. Proove’s Commitment to R&D Over 12,000 tests in 4 years giving Proove the world’s largest practice-based evidence database in personalized pain medicine and positions the Company to continue to lead the industry in R&D. Proove is the ONLY Company to have present any research this past year on the genetics of pain medicine at any scientific meeting related to pain medicine.

5. Professional Services Agreement Page 3 section 5 Fair Market Value Compensation and the first paragraph on page 4 last sentence: “All Clinical Research Services involving clinical study activities must be consistent with the clinical study protocol and the compensation for those study enrollments is outline in the protocol.” The physician’s compensation is timed based on each patient that is tested. An example of this time record can be found on the last page of the professional services agreement.

6. Professional Services Agreement cont’d The time estimate is evaluated by the submission of a Completed Case Report Form" ("CRF") shall mean a completed test requisition form with all required information and clinical assessments, all billing demographic information, a completed request for authorization (RFA) form, a completed PR2 or similar reports filed with the insurance carrier that outlines the request for the testing and utilization of the testing, and a reimbursement from the payer to quantify the economic outcomes, either Cost- Effectiveness, Cost-Benefit, Cost-Utilization, or Cost-Economic Analyses in accordance with all Food and Drug Administration ("FDA") and Study requirements, (ii) for a patient who properly qualified, participated in and completed the Study in accordance with all Study requirements, and (iii) which the Sponsor determines can be used in all analyses of the Study results. Its important to remember that both the clinical and economic components of the study are reviewed.

7. Professional Services Agreement cont’d The study concluded that their assessment of the fair market value and commercial reasonableness of the compensation to be paid to Proove’s contract physicians was derived by (a) reviewing the nature and complexity of the subject services and (b) analyzing benchmark surveys of physician compensation, the hourly rates paid for consultants and thought leaders, the rates paid to physicians in comparable professional services agreements, and the costs for alternative sources of data. In accordance with the foregoing and as further detailed in the accompanying report, it is our opinion that the fair market value and commercially reasonable compensation to be paid to the contracted physicians for collection of clinical drug research, is reasonably represented in the range of:

8. Professional Services Agreement cont’d ONE HUNDRED FIFTY DOLLARS PER HOUR TO TWO HUNDRED DOLLARS PER HOUR ($150/$200) The benefits of our testing can be found in four primary areas, the patient, the physician the payers and Proove. The patient realizes evidence based medical care, compensation for participation in the clinical studies without the burden of a balnce bill for the test and leading edge testing. For the physician participation in clinical research, compensation for providing their services, evidenced based medication and the opportunity to evaluate their patients against other patients. The payer community receives economic analysis on our testing, physician utilizing the test reports, centered on evidenced based medical guidelines coupled with a positive ROI, and finally for Proove providing the plat form to change the face of personalized medicine, R&D for additional tests, and ultimately improving people’s lives.

9. Dr. Schwarz - Executive Director of R&D John Hubbard - Director of Clinical Services and Acct Mgmt Intro to R&D Team Derrick Holman – Clinical Science Liaison Tobore Onojihafia – Manager of Clinical Affairs